R. Carruthers Net Worth

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Carruthers BBI stock SEC Form 4 insiders trading

R has made over 1 trades of the Brickell Biotech Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 24,000 units of BBI stock worth $50,160 on 2 December 2016.

The largest trade he's ever made was buying 24,000 units of Brickell Biotech Inc stock on 2 December 2016 worth over $50,160. On average, R trades about 4,800 units every 0 days since 2015. As of 2 December 2016 he still owns at least 24,000 units of Brickell Biotech Inc stock.

You can see the complete history of Mr. Carruthers stock trades at the bottom of the page.

R. Carruthers biography

R. Michael Carruthers is Chief Financial Officer of the Company. Mr. Carruthers has served as Brickell’s Chief Financial Officer since 2017. He has over 20 years of experience serving as the Chief Financial Officer for publicly-traded pharmaceutical companies. Mr. Carruthers previously served as Interim President of Nivalis Therapeutics (Nasdaq: NVLS), a pharmaceutical company that focuses on the discovery and development of product candidates for cystic fibrosis, beginning in January 2017 until August 2017 and Chief Financial Officer and Secretary since February 2015. From 1998 to 2015, he served as Chief Financial Officer for Array BioPharma (Nasdaq: ARRY), a biopharmaceutical company that focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer and other diseases. Prior to this, his professional experience included serving as Chief Financial Officer of Sievers Instrument, treasurer and controller for the Waukesha division of Dover Corporation and accountant with Coopers & Lybrand. Mr. Carruthers received a B.S. in accounting from the University of Colorado and a M.B.A. from the University of Chicago.

How old is R Carruthers?

R Carruthers is 62, he's been the Chief Financial Officer of Brickell Biotech Inc since 2019. There are 4 older and 12 younger executives at Brickell Biotech Inc. The oldest executive at Brickell Biotech Inc is Albert Nicholas Marchio II, 69, who is the Chief Financial Officer.

What's R Carruthers's mailing address?

R's mailing address filed with the SEC is C/O BRICKELL BIOTECH, INC., 5777 CENTRAL AVENUE, SUITE 102, BOULDER, CO, 80301.

Insiders trading at Brickell Biotech Inc

Over the last 5 years, insiders at Brickell Biotech Inc have traded over $0 worth of Brickell Biotech Inc stock and bought 584,350 units worth $353,337 . The most active insiders traders include Vijay B Samant, Monica E. Luchi y Gary A Lyons. On average, Brickell Biotech Inc executives and independent directors trade stock every 16 days with the average trade being worth of $51,782. The most recent stock trade was executed by Reginald L Hardy on 23 July 2021, trading 200,000 units of BBI stock currently worth $134,000.

What does Brickell Biotech Inc do?

Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on the development of innovative and differentiated prescription therapeutics for debilitating skin diseases with a focus on its lead asset sofpironium bromide for the treatment of hyperhidrosis. Brickell's executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta® and Juvederm®. Brickell's strategy is to leverage this experience to in-license, acquire, develop and commercialize innovative and differentiated pharmaceutical products that Brickell believes can be successful in the marketplace and transform lives by solving currently unmet patient needs.

Brickell Biotech Inc executives and stock owners

Brickell Biotech Inc executives and other stock owners filed with the SEC include:

• Vijay Samant,
  Director
• Attorney Robert Busard Brown,
  CEO & Director
• Deepak Chadha,
  Chief R&D Officer
• Reginald L. Hardy M.B.A., R.Ph.,
  Co-Founder & Chairman
• Dennison Veru,
  Director
• Gary Lyons,
  Director
• Adam Levy,
  Chief Business Officer
• Deepak Chadha,
  Chief Research and Development Officer
• David McAvoy,
  Chief Compliance Officer, General Counsel, Assistant Secretary
• Jose Breton,
  Chief Accounting Officer, Controller
• R. Carruthers,
  Chief Financial Officer
• Andrew Sklawer,
  Co-Founder, Chief Operating Officer, Secretary
• Robert Brown,
  Chief Executive Officer, Director
• Reginald Hardy,
  Chairman of the Board, Co-Founder
• Sue Fattor,
  Head of Human Resource
• Aron Aizenstat M.B.A., P.M.P.,
  VP of Corp. Devel. & Operations
• Gary S. Walker,
  Chief Marketing Officer
• David R. Mcavoy J.D.,
  Gen. Counsel & Chief Compliance Officer
• Jose Breton,
  Controller & Chief Accounting Officer
• Albert Nicholas Marchio II,
  Chief Financial Officer
• Sanjeev Ahuja,
  Chief Medical Officer
• George B Abercrombie,
  CHIEF EXECUTIVE OFFICER
• Monica E. Luchi,
  Chief Medical Officer
• Albert N Ii Marchio,
  Chief Financial Officer